NASDAQ · LBPH
Healthcare · Biotechnology
$59.98
Up+$0.00 (+0.00%)
Updated Sep 14, 2026, 12:18 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LBPH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning LBPH.
LBPH research
Company profile and research snapshot.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2024 | HC Wainwright & Co. | Neutral | — |
| Oct 15, 2024 | Truist Securities | Hold | — |
| Oct 14, 2024 | B. Riley Securities | Neutral | — |
| Oct 14, 2024 | Cantor Fitzgerald | Neutral | — |
| Sep 18, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 17, 2024
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sales of Longboard Pharmaceuticals, Inc. to H. Lundbeck A/S and ARC Document Solutions, Inc. to TechPrint Holdings, LLC. The firm may seek increased consideration for shareholders and additional disclosures.
The Motley Fool · Jan 17, 2024
You might say that this biotech stock is magnificent.
Benzinga · Jan 16, 2024
Cantor Fitzgerald has decided to maintain its Overweight rating of Longboard Pharmaceuticals (NASDAQ:LBPH) and raise its price target from $55.00 to $60.00. Shares of Longboard Pharmaceuticals are trading down 0.43% over the last 24 hours, at $23.35 per share. A move to $60.00 would account for a 156.96% increase from the current share price. About Longboard Pharmaceuticals Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, ...Full story available on Benzinga.com
Zacks Investment Research · Jan 5, 2024
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LBPH.
No results
No recent SID articles mention LBPH.
